Clinical trial · Observational
A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
Development and Validation of a New Prognostic Score Model Combining TNM Stage With Immune Risk Factors for Postoperative Pancreatic Ductal Adenocarcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The AJCC TNM staging system is the prevailing method in prognostic evaluation of pancreatic ductal adenocarcinoma (PDAC) at present , but it did not include factors such as the tumor immune microenvironment that are known to exert a profound impact on patients'clinical outcome. This study was aimed to develop a comprehensive and effective prognostic score model to predict prognosis and guide clinical management for postoperative PDAC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms Pancreatic | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pancreatic cancer surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- The training cohort
- description
- To develop the prognostic model, 302 cases of postoperative PDAC were included in the final analysis and divided into the training and validation cohort by stratified sampling with 7:3 ratio (The training cohort: n=212; The validation cohort: n=90).
- interventionNames
- Procedure: pancreatic cancer surgery
- label
- The validation cohort
- description
- To develop the prognostic model, 302 cases of postoperative PDAC were included in the final analysis and divided into the training and validation cohort by stratified sampling with 7:3 ratio (The training cohort: n=212; The validation cohort: n=90).
- interventionNames
- Procedure: pancreatic cancer surgery
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- after pancreatic cancer surgery until october 31, 2020
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Pathologically confirmed PDAC 2. Achievement of surgical resection (including radical or palliative surgery) Exclusion Criteria: 1. Lost to follow-up 2. Simultaneous presence of other tumors 3. Died in three months after surgery
References
Publications (0)
Data not yet available